Drug Database
RA

rat nerve growth factor (Nobex)

✓ Approved

Sinobioway Biomedicine · NGFR

What is rat nerve growth factor?

rat nerve growth factor is a therapeutic agent developed by Sinobioway Biomedicine. It is approved for therapeutic indications via injectable (others).

Drug Profile

Brand NamesNobex
CompanySinobioway Biomedicine
Molecular TargetNGFR
RouteInjectable (Others)
StatusApproved
Sources: ClinicalTrials.gov, Sinobioway Biomedicine

Mechanism of Action

Molecular Targets

rat nerve growth factor acts on 1 molecular target:

NGFRnerve growth factor receptor (Gp80-LNGFR, TNFRSF16)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

rat nerve growth factor is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Injury, poisoning and procedural complicationsCranial nerve injury✓ Approved

Related Research Articles

PubMedFrontiers in immunology2026-10-15

The effect of low-temperature-induced immune activation in elderly idiopathic facial palsy: the association between Th1/Th2 imbalance and facial nerve inflammation.

Tang Xing X, Ji Ziqin Z, Xiao Xueling X, Zhu Tongtong T et al.

The pathogenesis of idiopathic facial palsy in the elderly has not been fully elucidated. Recent studies have shown that exposure to low temperatures may participate in the pathological process through immune-mediated pathways. This article reviews that cold stimulation can disrupt the Th1/Th2 immune balance, manifested as reduced secretion of Th1-type cytokines and upregulation of Th2-type cytokines, thereby inducing peripheral inflammatory responses around the facial nerve, leading to nerve edema, demyelination, and conduction dysfunction. Due to the immune aging characteristics of the elderly population, including the reduction of the initial T cell pool, the imbalance of pro-inflammatory and anti-inflammatory factor ratios, and the decline in regulatory T cell function, they are more sensitive to the immune dysregulation induced by low temperatures and have a significantly increased risk of facial palsy. Clinical and animal experimental evidence supports this mechanism, suggesting that the serum IL-4/IFN-γ ratio may serve as a prognostic marker. Future multi-center studies are needed to verify the effectiveness of targeted immune regulation intervention through the Th2 pathway and explore the application value of low-temperature warning and individualized warming strategies in the prevention of facial palsy in the elderly.

PMID 42876459
Read full article →
PubMedLaryngoscope investigative otolaryngology2026-10-15

Extratemporal Facial Nerve: Surgical Landmarks, Risk Zones, and a Practical Framework for Safe Dissection.

Sagkriotis Emmanouil E, Gyftopoulos Kostis K, Goulioumis Anastasios A

To provide a clinically relevant synthesis of the extratemporal facial nerve, focusing on anatomical variability, surgical landmarks, and regions at risk of injury. A narrative review of the literature was performed, examining the extratemporal facial nerve across the parotid, midface, jawline, perioral, temporal, periorbital, and frontal regions. Emphasis was placed on branching patterns, depth relative to fascial planes, and surgically relevant anatomical relationships. The extratemporal facial nerve demonstrates considerable variability in course and branching. Regions where the nerve follows a superficial or less predictable trajectory represent areas of increased surgical risk. In contrast, consistent fascial planes and defined anatomical spaces may provide relatively safer corridors for dissection. A region-based, plane-oriented understanding of facial nerve anatomy reflects intraoperative conditions more closely than landmark-based descriptions alone. This approach may improve surgical orientation and reduce the risk of iatrogenic injury, particularly in procedures involving the parotid and midface. Level 5 (Narrative Review).

PMID 42876451
Read full article →
PubMedNature communications2026-10-15

Loss of NCOA6 protein causes aggressive prostate cancer with EGFR overexpression and dependency.

Liu Yonghong Y, Tong Zhangwei Z, Mo Qianxing Q, Peng Xiaohui X et al.

Loss of tumor suppressors can drive carcinogenesis while simultaneously creating actionable therapeutic vulnerabilities. Epidermal growth factor receptor (EGFR) is frequently overexpressed in prostate cancer (PCa), yet EGFR inhibitors have shown limited clinical benefit, and the basis for this variability remains unclear. Here, analysis of 1,719 human PCa specimens reveals frequent downregulation of the nuclear receptor coactivator 6 (NCOA6), particularly in metastatic disease. Genetic loss of NCOA6 accelerates tumor growth in human PCa xenografts, induces prostate tumorigenesis in mice, and cooperates with Pten haploinsufficiency to drive aggressive metastatic PCa. Mechanistically, NCOA6 forms a repressive complex with nuclear transcription factor Y (NFY) at a distal EGFR enhancer, blocking p300 recruitment and limiting EGFR transcription. Loss of NCOA6 derepresses EGFR, causing EGFR overexpression and rendering both androgen-sensitive and castration-resistant PCa highly dependent on EGFR signaling and exquisitely sensitive to EGFR inhibition. These findings identify NCOA6 as a potent tumor suppressor and a clinically relevant biomarker to stratify PCa patients most likely to benefit from EGFR-targeted therapy.

PMID 42875450
Read full article →
PubMedFrontiers in ophthalmology2026-10-15

Activating transcription factor 6 is involved in the beneficial effects of growth hormone-releasing hormone antagonists in the corneal endothelium.

Sarker Md Matiur Rahman MMR, Fakir Saikat S, Sigdel Madan M, Barabutis Nektarios N

The corneal endothelium maintains eye transparency through fluid regulation, and its dysfunction has been associated with impaired vision. This study is focused on the possible involvement of activating transcription factor 6 (ATF6) in the beneficial effects of Growth Hormone - Releasing Hormone antagonists (GHRHAnt) in corneal cells. ATF6 is a UPR sensor involved in barrier function, previously shown to exert anti-inflammatory activities. The aim of this study is to evaluate involvement of ATF6 in the effects of GHRHAnt in the corneal endothelium. MTT assay was used to measure the cell viability of ATF6 modulator. We demonstrated the efficient ATF6 manipulation by AA147 and Ceapin-A7, which are specific ATF6 modulators. Western blot analysis was used to detect the protein expression levels. FITC-dextran assay and DCFDA were utilized to measure paracellular permeability and reactive oxygen species generation, respectively. AA147 enhanced Grp94 and BiP expression, both being downstream ATF6 targets, whereas Ceapin-A7 exerted the opposite effects. Then, we investigated the possible involvement of ATF6 in the protective activities of GHRHAnt in the corneal endothelium. ATF6 activation enhanced the protective effects of GHRHAnt by reducing paracellular permeability and ROS generation, while ATF6 inhibition exerted the opposite effects. Our study suggests that ATF6 mediates - at least in part - the beneficial effects of GHRHAnt in the cornea.

PMID 42876753
Read full article →
PubMedFrontiers in oral health2026-10-15

Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases.

Froum Scott S, Estrin Nathan N, Pico Gianna G, Yakubov Mikhail M et al.

Inferior alveolar nerve (IAN) injury represents a substantial complication in oral and maxillofacial surgery, often leading to persistent neurosensory dysregulation with limited effective treatment options. This narrative review analyzes the biological rationale for regenerative peptides as potential adjuncts in peripheral nerve repair and presents three hypothesis-generating clinical cases managed using a multimodal approach. Experimental evidence suggests that peptides, such as BPC-157, thymosin β4 derivatives (TB-500), and ARA-290, may affect biological pathways implicated in peripheral nerve repair, such as inflammation regulation, cytoprotection, angiogenic signaling, extracellular matrix remodeling, Schwann cell biology, and axonal regeneration. Nonetheless, these processes have been demonstrated mainly in preclinical models and have not been directly established in patients with IAN injury. Three illustrative clinical cases treated with a multimodal method incorporating peptide agents, dexamethasone, and local anesthetic showed neurosensory recovery during follow-up. Nonetheless, owing to the uncontrolled nature of these observations, spontaneous recovery and other confounding factors cannot be excluded, and causality cannot be established. Consequently, a phase-based intervention framework is proposed, emphasizing a biologically informed phase-mediated management system. Despite promising biological rationale, peptide-based interventions remain investigational, with unresolved questions concerning safety, delivery, optimal dosing, and long-term outcomes. Rigorous, controlled clinical trials and standardized outcome measures are required to validate efficacy and define their role with contemporary management paradigms for IAN injury.

PMID 42876687
Read full article →
PubMedJournal of anatomy2026-10-15

Quantitative analysis of intrarenal nerve-associated profiles in the human foetal kidney between 14 and 30 gestational weeks: An S100 immunohistochemical study.

Petrović Ivan I, Balenović Ana A, Bosanac Milana M, Stanković Srdjan S et al.

Quantitative data on the spatial development of intrarenal S100-positive nerve-associated profiles in human foetal kidneys remain limited, despite the established importance of renal nerves. Building on the previously published semiquantitative observations, this study aimed to generate a quantitative, compartment-resolved map of S100-positive nerve-associated profiles in human foetal kidneys. Formalin-fixed, paraffin-embedded human foetal kidney specimens ranging from 14 to 30 gestational weeks were analysed using S100 immunohistochemistry. Based on gestational age, specimens were divided into three groups: ≤18 gestational weeks (G1, n=6), 19-24 gestational weeks (G2, n=6), and ≥ 25 gestational weeks (G3, n=6). Cortical maturation was assessed by measuring nephrogenic zone and maturation zone thickness and calculating the cortical maturation index (CMI). Morphometric analysis of cortical S100-positive nerve-associated profiles was performed using digital image analysis. Distribution patterns of S100-positive profiles were assessed qualitatively. Group-wise analysis demonstrated significantly lower cortical S100-positive area in G1 compared with G2 and G3 (median: 985 μm2 vs. 1733 μm2 and 2400 μm2, respectively; p < 0.001). Cortical S100-positive area increased significantly with gestational age and foetal weight and showed an inverse correlation with CMI (ρ = -0.410, p < 0.001), indicating parallel progression of S100-positive area and cortical maturation. In multivariate linear regression analyses, cortical S100-positive area remained independently associated with gestational age (β = 125.0, p = 0.006) and foetal weight (β = 1.50, p = 0.006), explaining 57.6% of the variance (adjusted R2 = 0.485). Perivascular localisation was the most frequently observed distribution pattern, while juxtaglomerular and intraglomerular patterns were also identified, including in the earliest gestational-age group. This study provides the first quantitative, compartment-resolved analysis of intrarenal nerve-associated profiles in the human foetal kidney. Cortical S100-positive area increases with gestational age in parallel with cortical maturation and shows a predominantly perivascular distribution, consistent with a neurovascular co-development model and establishing a morphological framework for future functional studies of renal innervation.

PMID 42876030
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about rat nerve growth factor